Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Enterprise Value: 2009-2024

Historic Enterprise Value for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $1.0 billion.

  • Ani Pharmaceuticals' Enterprise Value rose 55.37% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 188.37%. This contributed to the annual value of $1.0 billion for FY2024, which is 12.34% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Enterprise Value stood at $1.0 billion for FY2024, which was up 12.34% from $905.8 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Enterprise Value high stood at $1.0 billion for FY2024, and its period low was $346.0 million during FY2020.
  • In the last 3 years, Ani Pharmaceuticals' Enterprise Value had a median value of $905.8 million in 2023 and averaged $857.6 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Enterprise Value plummeted by 49.36% in 2020, and later surged by 39.49% in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Enterprise Value stood at $346.0 million in 2020, then spiked by 39.38% to $482.3 million in 2021, then spiked by 34.64% to $649.4 million in 2022, then spiked by 39.49% to $905.8 million in 2023, then rose by 12.34% to $1.0 billion in 2024.